Slingshot members are tracking this event:
Sangamo Therapeutics (SMGO) earns FDA Fast Track Designation for SB-318 And SB-913 in treatment of Mucopolysaccharidosis (MPS) I and II
Slingshot Insights Explained
Jun 13, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Fda Fast Track Designation, Sb-318, Sb-913, Mucopolysaccharidosis